Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

The site in the European biotech hub of Basel, Switzerland, is run by Boehringer’s subsidiary NBE Therapeutics. Boehringer bought the Swiss biotech for $1.5 billion in 2020 in a deal centered ...

Evogene (EVGN) signed a definitive agreement under which ICL will acquire the majority of activity of Evogene’s subsidiary, Lavie Bio. As part ...

WATERTOWN, Mass., April 2, 2025 /PRNewswire/ -- Landmark Bio today announced it has been acquired by Artis BioSolutions ("Artis"), a newly launched company dedicated to streamlining the discovery ...

REHOVOT, Israel, April 21, 2025 /PRNewswire/ --Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and ...

NBE Therapeutics (NBE) a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to innovation in oncology and ...

The group’s designs, called Bio-e-Nails, use common ingredients obtained from algae or the hard exteriors of shellfish and other animals. They come in all shapes and sizes: Do you like long and ...